Skip to main content
TipRanks
Go Ultimate75% OFF

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Stock Statistics & Valuation Metrics

3 Followers

Total Valuation

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has a market cap or net worth of HKD 1.23B. The enterprise value is HKD 992.18M.

Market Cap
HKD 1.23B
Enterprise Value
HKD 992.18M

Share Statistics

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 420,477,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
420,477,300
Owned by Insiders
―
Owned by Institutions
0.19%

Financial Efficiency

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -21.33%.

Return on Equity (ROE)
-0.27
Return on Assets (ROA)
-0.19
Return on Invested Capital (ROIC)
-21.33%
Return on Capital Employed (ROCE)
-0.26
Revenue Per Employee
744.06K
Profits Per Employee
-1.05M
Employee Count
202
Asset Turnover
0.14
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is -4.56. ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s PEG ratio is -0.14.

PE Ratio
-4.56
PS Ratio
6.84
PB Ratio
1.67
Price to FCF
-4.42
Price to Operating Cash Flow
-4.48
PEG Ratio
-0.14

Income Statement

In the last 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had revenue of 150.30M and earned -212.92M in profits. Earnings per share was -0.51.

Revenue
150.30M
Gross Profit
134.99M
Operating Income
-217.26M
Pretax Income
-213.58M
Net Income
-212.92M
EBITDA
-203.03M
Earnings Per Share (EPS)
-0.51

Cash Flow

In the last 12 months, operating cash flow was -232.80M and capital expenditures -1.95M, giving a free cash flow of -234.76M billion.

Operating Cash Flow
-232.80M
Free Cash Flow
-234.76M
Free Cash Flow per Share
-0.54

Dividends & Yields

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-22.65%
Earnings Yield
-21.98%

Stock Price Statistics

Beta
0.70
52-Week Price Change
-60.87%
50-Day Moving Average
3.11
200-Day Moving Average
3.79
Relative Strength Index (RSI)
45.08
Average Volume (3m)
464.17K

Important Dates

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).

Last Earnings Date
Aug 26, 2026
Next Earnings Date
Mar 30, 2027
Ex-Dividend Date
―

Financial Position

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H as a current ratio of 3.83, with Debt / Equity ratio of 28.81%

Current Ratio
3.83
Quick Ratio
3.83
Debt to Market Cap
0.10
Net Debt to EBITDA
2.22
Interest Coverage Ratio
-42.05

Taxes

In the past 12 months, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has paid 28.25K in taxes.

Income Tax
28.25K
Effective Tax Rate
-0.00

Enterprise Valuation

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H EV to EBITDA ratio is -3.70, with an EV/FCF ratio of -3.20.

EV to Sales
4.96
EV to EBITDA
-3.70
EV to Free Cash Flow
-3.20
EV to Operating Cash Flow
-3.23

Balance Sheet

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has HKD 946.44M in cash and marketable securities with HKD 363.12M in debt, giving a net cash position of HKD 583.33M billion.

Cash & Marketable Securities
HKD 946.44M
Total Debt
HKD 363.12M
Net Cash
HKD 583.33M
Net Cash Per Share
HKD 1.39
Tangible Book Value Per Share
HKD 1.44

Margins

Gross margin is 94.57%, with operating margin of -134.78%, and net profit margin of -151.13%.

Gross Margin
94.57%
Operating Margin
-134.78%
Pretax Margin
-152.33%
Net Profit Margin
-151.13%
EBITDA Margin
-134.01%
EBIT Margin
-143.42%

Analyst Forecast

The average price target for ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
28.93%
EPS Growth Forecast
27.27%

Scores

Smart Score
1
AI Score
46